A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.
The global firm with extensive Indiana operations plans to occupy a 40,000-square-foot building to be constructed in the Purdue Research Park Aerospace District, a 980-acre technology park in West Lafayette.
An Indiana not-for-profit has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90 percent after re-acquiring rights to the medicine from Rodelis Therapeutics.
N. Clay Robbins, the president and CEO of the Lilly Endowment, has been given the additional title of chairman at the Indianapolis-based private charitable foundation.
It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.
Analysts have consistently given the Indianapolis-based company some of the lowest ratings among a group of 16 large drugmakers, but Lilly shares have been on a five-year rally.
Indianapolis Business Journal gathered leaders in the state’s commercial real estate and construction industry for a Power Breakfast panel discussion Sept. 10.
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
16 Tech would bring together many of Indianapolis’ existing strengths—our research universities, life sciences expertise and vibrant technology sector—to spark new companies and jobs.
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
Simon Property Group Inc. is proposing an estimated $20 million in improvements to Circle Centre mall, which spurred a downtown renaissance when it opened 20 years ago this month but now is showing signs of struggle.
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.
For two years, Eli Lilly and Co. has been building a team of immuno-oncology researchers in New York City and has struck a series of deals with other drug companies.
A new analysis shows attempts by drugmakers to raise prices are being wiped out in negotiations with managers of drug insurance benefits like Express Scripts Holding Co. and CVS Health Corp.
Education reform groups are struggling to raise money locally, even as Indiana is recognized as one of the friendliest in the nation for school reform ideas.
IBJ’s front-page article flies directly in the face of these business arguments. As quoted, the city of Indianapolis, which already has anti-discrimination protections for LGBT, has seen reductions in both high-tech jobs and highly educated workers.
